New Technology– category –
-
PD-(L)1×VEGF ADC: 87.5% ORR in SCLC patients at WCLC 2026
VCBeat China Overview Early clinical data presented at WCLC 2026 revealed that a combination therapy of a PD-(L)1×VEGF bispecific antibody and an ADC, developed by a Chinese firm, achieved an 87.5% objective response rate (ORR) in small ... -
Stanford Virtual Biotech: AI agents drug discovery specs 2026
DistilINFO USA Overview Stanford University School of Medicine researchers have unveiled a test of 'Virtual Biotech,' an innovative operational model where thousands of AI agents simulate the entire drug discovery workflow. This project ... -
MIT LNP Technique: Organ-specific RNA delivery method explained
MIT News USA Overview MIT researchers have developed a novel lipid nanoparticle (LNP) manufacturing technique that precisely controls particle size and shape, critical for targeted RNA drug delivery. This innovation significantly enhance... -
NTS231: Nutshell Therapeutics’ AI-driven 24-month IND timeline
AllSci USA Overview Nutshell Therapeutics received U.S. FDA Investigational New Drug (IND) clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2. Remarkably, this was achieved in just 24 months from target nominatio... -
AlphaFold: 2,800+ AI viral protein structures explained
Mirage News International Overview AlphaFold has significantly expanded its database to include AI-predicted protein complex structures for over 2,800 viruses, prioritizing those known to infect humans, to enhance global pandemic prepare... -
FDA: Non-animal testing standard roadmap and 2030 timeline
Vertex AI Search USA Overview The FDA announced plans to remove animal testing references from drug regulations, clarifying that companies can seek drug approval without animal data. This pivotal shift encourages the use of alternative m... -
Sotyktu: Bristol Myers Squibb’s first oral TYK2 inhibitor FDA specs
MarketBeat USA Overview Bristol Myers Squibb (BMS) announced FDA approval on March 6, 2026, for Sotyktu® (deucravacitinib), an oral selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of active psoriatic arthritis in adults. ... -
AI drug discovery: 80-90% Phase I success rate explained
World Health Expo International Overview AI-identified drug candidates have demonstrated an impressive 80-90% success rate in Phase I clinical trials, significantly surpassing the historical industry average. This breakthrough is driven ... -
Oral GLP-1 drugs: 2026 clinical trial bioavailability specs
Vertex AI Search (grounding-api-redirect) USA Overview New oral GLP-1 medications in clinical trials have significantly improved bioavailability through the use of novel absorption enhancers, overcoming traditional degradation challenges... -
Arbutus & Genevant Sue Federal Government for Patent Infringement on Moderna mRNA Vaccine LNP Components
Patent Docs United States Overview On September 11, 2026, Arbutus Biopharma and Genevant Sciences filed a patent infringement lawsuit against the U.S. Federal Government regarding the lipid nanoparticle (LNP) components used in Moderna’s...
